Abstract
Background: Systemic inflammation has been shown to be responsible of tumor growth and shortened survival. Advanced lung cancer inflammation index (ALI) was developed to assess inflammation and prognostic in lung cancer at the time of diagnosis. Therefore, the aim of this study was to explore the relationship between ALI and the prognosis of NSCLC.
Methods: Patients diagnosed with stage IV NSCLC at our institution between janv 2010 and janv 2013 were screened. ALI score was calculated as BMIxALB/NLR with BMI=body mass index, Alb=serum albumin and NLR=neutrophil lymphocyte ratio. Patients were divided into low inflammation (ALI>18) and high inflammation (ALI<18). Chi-squared test was performed to compare clinical characteristics in different groups. Kaplan-Meier and Cox regression model were used to determine independent prognostic factors.
Results Fifty eight patients were included. Median age was 61 years, all patients were male and 48.7 % had adenocarcinoma. Compared to patients with ALI score>18, Patients with ALI score <18 had a poor PS (p=0.006) and were less likely to receive chemotherapy (p=0.003). Median overall survival (OS) was 6.7month and month as opposed to11.3 month in patients with ALI>18 (p=0.043). On multivariate analysis, Performans status (p=0.006), CRP (p=0.007), receiving chemotherapy (p=0.003) and ALI score (HR=2.38; IC95% [1.00-5.67]; p=0.049) were independent prognostic factors for OS.
Conclusion: ALI is an easy to calculate tool to assess systemic inflammation in advanced NSCLC. Lower ALI could authenticate the patients with poor prognosis and be a useful marker in clinical practice.
- Copyright ©the authors 2016
